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The BCR-ABL negative chronic myeloproliferative disorders (CMPDs) are a group of stem cell 
clonal haematological malignancies characterised by abnormal proliferation and survival of one 
or more myeloid lineage cells. It has been proposed that they are caused by abnormalities in 
some signal transduction pathways mainly due to acquired somatic mutations, some of them in 
tyrosine kinase genes. One of the most prevalent mutations is V617F in the pseudokinase 
domain (JH2) coded by JAK2 exon 14. This mutation, reported in 2005, has been associated 
with nearly 95% of patients diagnosed of polycythaemia vera (PV) and near a half of the 
patients with essential thrombocythaemia (ET) and primary myelofibrosis (MF). However, the 
frequency of this mutation is below 20% for the remaining chronic myeloproliferative disorders 
and is absent in lymphoid neoplasms. JAK2V617F has been an important milestone in the 
knowledge of the molecular mechanisms leading to classic myeloproliferative disorders. 
However, there are still some patients with PV, ET and MF lacking V617F whose molecular 
defect is unknown. The disease in these cases could be due to other abnormalities in JAK2 or 
other related genes. In fact, in a few cases new point mutations have been reported, affecting 
also the JH2 domain, and one mutation affecting the JH1 domain [1] and reviewed in [2], some 
of them in other haematological malignancies. In addition, 10% of patients diagnosed of MF 
and some with ET show somatic activating mutations in the thrombopoietin receptor gene 
(MPL) inducing constitutive cytokine-independent activation of the JAK-STAT pathway. 
Recently, different groups have described novel mutations in JAK2 exon 12 in V617F-negative 
CMPD patients [2], [3], [4], [5] and [6]. The mutations reported affect amino-acid residues 
between F537-E544 and lie in a highly conserved region proximal to the JH2 domain of this 
gene. These findings support the idea that JAK2 is one of the main candidates to study the 
pathogenesis of these disorders. In addition, the patients with JAK2 exon 12 mutations seem to 
show distinctive clinical features different from V617F-positive patients such erythrocytosis, 
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and also a distintive bone marrow morphology [5] and [7]. These findings could define a new 
myeloproliferative variant associated with erythrocytosis but this is still unclear [4]. 
We have studied the coding region of JAK2 (25 coding exons) in 39 patients diagnosed of 
classic (PV n=19, TE n=7, MF n=2) and atypical CMPD (n=11) by denaturing high 
performance liquid chromatography (dHPLC) with the WAVE® 4500 System (Transgenomic 
Ltd, Omaha, NE) and direct sequencing of the abnormal elution profiles. Sequencing results 
were analyzed with Mutation Surveyor v2.51 software (SoftGenetics, LLC, State College, PA), 
and abnormal profiles were checked manually. All the patients were negative for JAK2V617F 
analyzed by amplification refractory mutation system PCR (ARMS-PCR) and confirmed by 
dHPLC. Twenty-one normal samples were also included as control group in order to detect 
potential differences in the frequencies of the polymorphisms observed in the analyses. 
Two of the 19 PV patients carried silent variants in exons 19 and 25, 96506 C>T (D820D) and 
141607 C>T (exonic non-coding region) respectively, not previously described as 
polymorphisms in the NCBI SNP database (http://www.ncbi.nlm.nih.gov/projects/SNP/). Both 
of these mutations were in heterozygous state and were not detected in the control group. If 
either both changes are rare polymorphisms or silent mutations affecting jak2 function (by 
means, for example, of increased mRNA stability) remains to be elucidated.  
Another two of the 19 PV patients harbored JAK2 exon 12heterozygous mutations (Fig. 1). One 
male patient had a 6 bp in-frame deletion, between positions 1627 to 1632 of the cDNA 
sequence (Fig. 1A and B). This mutation results in the loss of two aminoacids (E543-D544del) 
and it has been described previously in six PV patients (five female and one male) [5] and one 
female patient with idiopathic erythrocytosis (IE) [6]. The other patient, also male, had another 
6 bp in-frame deletion, located between positions 1624 to 1629, (Fig. 1A and C) resulting also 
in the loss of two aminoacids (N542-E543del). This mutation has been described in eleven PV 
patients (five female and six male) [3], [5], [7] and [8] and five IE patients (three female and 
two male) [6] . Both of them are the most frequent recurrent non-V617F mutation in JAK2 and 
lie in the same “hot” region where other indel mutations have been described. No other mutation 
was identified in the 25 JAK2 coding exons in the remaining 35 V617F-negative CMPDs 
patients, despite the fact that dHPLC is a very sensitive method. 
In our series, twenty CMPDs samples other than PV or IE have been included. No JAK2 
mutations were found in these samples, confirming that JAK2 exon 12 mutations are specific for 
PV and IE phenotype as reported by other groups [5] and [7]. 
The data presented here support the idea that other somatic aberrations remain to be identified, 
and also that some PV patients have mutations other than V617F in JAK2 or in other genes. In 
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addition, the frequency of JAK2 exon 12 mutations in PV V617F-negative patients (2/19 or 
10.5%) was significantly lower in our series than the frequency observed by other groups (30-
100%) [3], [4], [5] and [7], maybe due to the small size of our series. In addition, both mutations 
in exon 12 were found in male patients in contrast with the slightly female predominance 
described by other groups [3] and [6]. However, despite the discrepancy in the frequencies 
observed, the mutations reported here reside in the same JAK2 mutational “hot spot region”. 
This region must play an important role in JAK2 activity that needs to be investigated in further 
analyses. 
The data presented here reinforce the importance of searching mutations by screening methods 
in JAK2 exon 12, at least for some CMPDs, in addition to the highly prevalent V617F. This will 
lead to a better diagnosis of some patients, who might also become potential candidates for 
future anti-jak2 therapies. 
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Figure 1.  
Panel A. Mutational analysis by denaturing high performance liquid chromatography (dHPLC) of JAK2 
exon 12 in 39 samples from CMPDs patients. There are different elution profiles: green profile from 
patients samples lacking mutations, blue profile from heteroduplex mutant-normal (mutant created by 
mutagenesis and used as reference for the analyses), orange and red profiles from patient samples with 
mutations in JAK2 exon 12. 
Panel B. JAK2 exon 12 sequencing results from the 17266 patient sample with orange profile. The 
sample sequence has been compared with the genomic reference sequence obtained from EnsEMBL 
(http://www.ensembl.org) showing a 6-bp in-frame deletion (GAAGAT). This mutation results in the loss 
of two aminoacids (E543-D544del). 
Panel C JAK2 exon 12 sequencing results from the 22068 patient sample with red profile. Comparing this 
sequence with the genomic reference sequence, a 6-bp deletion (AAGATT) can be observed, resulting in 
the loss of two aminoacids (N542-E543del)  
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